Shugeng Cao, PhD
- Associate Member
Cancer Biology Program
University of Hawaii Cancer Center
- Associate Professor
Daniel K. Inouye College of Pharmacy
University of Hawaii at Hilo
- PhD (Organic Chemistry), National University of Singapore
- Post-doctorate, Virginia Tech & Harvard Medical School
Nature has been a rich source for drug discovery for centuries. Many anticancer drugs were developed from plant metabolites. However, microorganisms from plants, oceans and insects etc. are underexplored natural sources for anticancer drug discovery. (i) It is well known that bacteria are producers of variety of bioactive compounds. But it is fair to say that no single strain has been entirely studied for its secondary metabolites; and not much attention has been paid to some bacteria (for example, deep-sea bacteria, bacteria associated with arthropods, and bacteria from lower animals etc.) that are therefore, underexplored for their bioactive compounds. (ii) Each of the about 250,000 land plant species hosts one or more endophytes. An endophyte could be either a bacterium or a fungus. Endophytic fungi have been studied, but few of these endophytes have been characterized, and they are very underexplored for their secondary metabolites when compared to fungal plant pathogens and fungal soil isolates. (iii) Oceans cover nearly 70% of the earth's surface and possess nearly 300,000 described species of plants and animals from marine sources, comprising about half of the total biodiversity. However, the development of marine natural products as therapeutic agents is still in its early stages due to the lack of an analogous ethno-medical history as compared to terrestrial habitats, together with the relative technical difficulties in collecting the marine floral samples. On the other hand, microorganisms can grow in almost all marine habitats, for example, coral, algae, sponges, fishes and sediments etc., but they are underexplored. Hence, microorganisms in the marine environment are also an extremely rich source for anticancer drug discovery.
The Cao laboratory focuses on exploring bacteria, endophytic fungi and marine-associated microorganisms for anticancer drug discovery. This will be carried out through collaboration between different disciplines at the UH Cancer Center with novel approaches to guide the identification of strains that have the potential to produce anticancer drug leads; novel dereplication technique (e.g., LC/MS etc.) to identify strains that produce novel compounds; structure elucidation of active compounds by NMR, chemical modifications and degradations, and x-ray analysis; high throughput screening through collaboration with oncologists; and genome sequencing if necessary.
The Cao Lab also works on herbal medicines used for diseases related to cancer and diabetes, etc., and small molecules with various biological functions in bacteria and the human body.
- Senger DR, Cao S*. (2016) Diabetic Wound Healing and Activation of Nrf2 by Herbal Medicine. J Nat Sc (2012)i, 2(11):e247.
- Briggs KJ, Koivunen P, Cao S, Backus KM, Olenchock BA, Patel H, Zhang Q, Signoretti S, Gerfen GJ, Richardson AL, Witkiewicz AK, Cravatt BF, Clardy J, KaelinWG, Jr*. (2016) Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cystein." Cell, 166(1), 126-139.
- Senger DR, Hoang MV, Kim KH, Li C, Cao S*. (2016) Anti-inflammatory activity of Barleria lupulina: Identification of active compounds that activate the Nrf2 cell defense pathway, organize cortical actin, reduce stress fibers, and improve cell junctions in microvascular endothelial cells. J Ethnopharmacology, 193, 397-407.
- Li C-S, Ren G, Yang B-J, Miklossy G, Turkson J, Fei P, Ding Y, Walker LA, Cao S*. (2016) Meroterpenoids with anti-proliferative activi-ty from a Hawaiian-Plant Associated Fungus Peyronellaea coffeae-arabicae FT238. Org Lett, 18(10), 2335-2338.
- Li C-S, Ding Y, Yang B-J, Miklossy G, Yin H-Q, Walker LA, Turkson J, Cao S*. (2015) A Novel Metabolite with a Unique 4-pyranoneâ€“Îł-lactamâ€“1,4-thiazine moiety from a Hawaiian-Plant Associated Fungus. Org Lett, 17(14), 3556-3559.
- Cheng B, Cao S, Vasquez V, Annamalai T, Tamayo-Castillo G, Clardy J, Tse-Dinh YC. (2013) Identification of anziaic acid, a lichen depside from Hypotrachyna sp., as a new topoisomerase poison inhibitor. PLoS One, 8(4):e60770. PMID: 23593306 [PubMed - indexed for MEDLINE].
- Cao S, Cryan L, Habeshian KA, Murillo C, Tamayo-Castillo G, Rogers MS, Clardy J. (2012) Phenolic compounds as antiangiogenic CMG2 inhibitors from Costa Rican endophytic fungi. Bioorg Med Chem Lett, 22(18): 5885-8. PMID: 22910038 [PubMed - indexed for MEDLINE].
- Cao S, McMillin DW, Tamayo G, Delmore J, Mitsiades CS, Clardy J. (2012) Inhibition of tumor cells interacting with stromal cells by xanthones isolated from a Costa Rican Penicillium sp. J Nat Prod, 75(4):793-7. PMID:22458669 [PubMed - indexed for MEDLINE].
Publication list via PubMed
- S. Cao, Co-Investigator / Donald Senger, Principal Investigator
"Remedying Dysfunctional Angiogenesis and Tissue Ischemia with Barleria lupulina"
- S. Cao, Principal Investigator
Hawaii Community Foundation (HCF)
"Novel STAT3 inhibitors as anti-cancer agents from Hawaiian fungi"
2015-2016 (no cost extension to 2017)
- S. Cao, Co-PI / lead PI: Dr. Michael Hadfield
Gordon & Betty Moore Foundation
"The bacterial basis of larval recruitment for benthic marine communities"